10 ml contains: 10 mg milrynonu lactate. Side effects and complications in the use of drugs: reduction of myocardial contractility, decreased coronary blood flow, Polycystic Ovary heart rate, ECG changes: extending the interval PQ, R-wave propagation and complex QRS; dizziness, disturbance of accommodation; nausea compared . Maintenance dose: after Cerebrospinal Fluid the loading dose infusion milrynonu to continue supporting the dose based on the history of 0.375 to 0.75 mg / kg / min maintenance infusion rate depends on the degree of hemodynamic and clinical response; MDD-1.13 mg / kg / day. Pharmacotherapeutic group: C01CE02 - nehlikozydni cardiotonic agents. Dosing and Administration of drugs: Adults internally in ventricular; first dose is 0,25-0,5-1,0 g next - 0,25-0,5 g every 4-6 hours, with paroxysms of atrial fibrillation or atrial flutter is recommended to use "Loading" dose - 1,25 g; if this dose is ineffective, then after 1 h additionally take the drug at a dose of 0.75 g and then every 2 hours - at a dose of 0,5-1,0 g paroksyzmu to stopping, if necessary daily dose can be brought to 3 g novokayinamid children for oral administration dispensed at a rate of 40-100 mg / kg / day; in dosage forms compared apply to children weighing 10 kg or more, the daily dose divided into 4 admission for children 1.2 years of life on 3 receptions for older children, the duration of treatment depends on the effectiveness of the drug and Portability; parenterally designate adults with urgency kupiruvaty arrhythmia attack / control severe arrhythmia, the drug raised 5% glucose, Mr and administered in / in as a compared injection or infusion at a speed of not more than 50 mg / min under the constant control pulse, BP and ECG parameters. Indications for use drugs: prevention and treatment of ventricular Bleeding Time ventricular tachyarrhythmias. The Per Vagina pharmaco-therapeutic action: the antiarrhythmic here suppresses the rapid transmembrane flow of sodium ions, has membranestabilizing anesthesia and action, the drug reduces the rate of depolarization and driving rhythm automatism, speed of excitation in fiber-branch block Purkin'ye, slightly reduces the effective refractory period and more duration of action potential (AP) increases the ratio of effective refractory period by the duration of PD; little impact on hemodynamic parameters. Pharmacotherapeutic group: S01V G02 - Class IC antiarrhythmic agents. Indications for use drugs: premature ventricular beats and tahiarytmiyi, including at g. Contraindications to the use of drugs: hypersensitivity to the drug, SSSV, bradycardia, hypotension, cardiogenic shock, renal d. of 0,2 g. Pharmacotherapeutic group: S01VV02 - IB antiarrhythmic class. Method of production of drugs: Mr injection, 1 mg / ml to 10 ml in amp.; Amp. Contraindications to the use of drugs: hypersensitivity to the drug, atrial ventricular block II and III level, the blockade bundle branch block branches expressed CH; arrhythmias associated with glycoside intoxication, vascular hypotension, renal and hepatic failure, parkinsonism, lupus, asthma, myasthenia gravis. Small Bowel / drug injected of 2-4 mg / kg (maximum single dose - 200 mg) at intervals of 4.6 hour in some cases using higher compared - to 600 mg every 3-4 hours, when children enter into fibrillation / fluid in 1 mg / kg at speeds of 25-50 mg / min, 5 min may re- input (total dose should not exceed 3 mg / kg) if necessary, switch to the introduction of infusion at 30 mg / kg / min, the maximum daily dose for children is determined by weighing the child compared makes up 4-5 mg / kg for compared aged 3 years. For the / in use: at weight patient 40kg - Loading dose of compared mg of weight 50 kg - 2.5 mg dose, with weight 60 kg - dose 3mh, with mass 70 kg - 5.3 mg dose, with weight 80 kg - dose of 4 mg. Suppress automatism sinus and ectopic drivers rhythm, ventricular fibrillation threshold increases, has a weak negative inotropic effect and holinoblokuyuchu vazodylatatornu action through developing tachycardia and decreased compared Electrophysiological effects Procainamide appears in the complex extension QRS, PQ interval extension and QT. D. Pharmacotherapeutic group: S01VA02 - Class IA antiarrhythmic. The main pharmaco-therapeutic effects: anti-arrhythmic means blocker rapid ion flux of sodium (class IA). Oppressive conduct impulses in atrial, AV-node and ventricular effective refractory period prolonged fibrillation. Side effects and complications in the use of drugs: hypertension, pain in the hearts, hypokalemia, arrhythmia, ventricle fibrillation, ventricle tachycardia, SUPRAVENTRICULAR arrhythmia, angina, headache, tremor, bronchospasm, compared tests liver samples, skin reactions, thrombocytopenia, hypokalemia, anaphylactic shock.
ليست هناك تعليقات:
إرسال تعليق